PCI-34051

For research use only. Not for use in humans.

目录号：S2012

CAS No. 950762-95-5

PCI-34051是一种有效的，特异性的HDAC8抑制剂，无细胞试验中IC50为10 nM。比作用于HDAC1和6选择性高200多倍，比作用于HDAC2， 3，和10选择性高1000倍。PCI-34051可诱导半胱天冬酶依赖的凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1815.22	现货
10mg	RMB 1377.26	现货
100mg	RMB 9582.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达全国免运费分装免费

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的PCI-34051发表文献39篇：

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Cell Rep, 2021, 37(12):110129

PubMed: 34936867 ( click the link to review the publication )

Thyroid, 2021, 10.1089/thy.2020.0948

PubMed: 34235979 ( click the link to review the publication )

Tuberculosis (Edinb), 2021, 127:102062

PubMed: 33639591 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5783

PubMed: 33188197 ( click the link to review the publication )

Theranostics, 2020, 10(15):6790-6805

PubMed: 32550904 ( click the link to review the publication )

Cell Death Dis, 2020, 11(12):1036

PubMed: 33279948 ( click the link to review the publication )

FASEB J, 2020, 12

PubMed: 32281211 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(12):E4539

PubMed: 32630606 ( click the link to review the publication )

Am J Transl Res, 2020, 12(10):6187-6203

PubMed: 33194023 ( click the link to review the publication )

EXCLI J, 2020, 19:734-744

PubMed: 32636726 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12864

PubMed: 32733053 ( click the link to review the publication )

Theranostics, 2020, 10(16):7351-7368

PubMed: 32641996 ( click the link to review the publication )

Pathol Res Pract, 2020, 216(4):152867

PubMed: 32067803 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2947-2961

PubMed: 30987999 ( click the link to review the publication )

Cell Rep, 2019, 26(10):2608-2621.e6

PubMed: 30840885 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)E645

PubMed: 31083396 ( click the link to review the publication )

PLoS Genet, 2019, 15(2):e1007685

PubMed: 30779731 ( click the link to review the publication )

Biol Chem, 2019, 400(6):733-743

PubMed: 30521473 ( click the link to review the publication )

Nucl Med Biol, 2019, 74-75:1-11

PubMed: 31421440 ( click the link to review the publication )

Clin Hypertens, 2019, 25:13

PubMed: 31223486 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

J Med Chem, 2018, 61(22):10000-10016

PubMed: 30347148 ( click the link to review the publication )
Stem Cells Transl Med, 2018, 10.1002/sctm.18-0057

PubMed: 30426726 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):635-646

PubMed: 29917168 ( click the link to review the publication )

Virol Sin, 2018, 33(5):418-428

PubMed: 30328580 ( click the link to review the publication )

Exp Mol Med, 2017, 49(2):e297

PubMed: 28232663 ( click the link to review the publication )

Chemistry, 2017, 23(13):3107-3116

PubMed: 27922200 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(10):2685-2692

PubMed: 27459069 ( click the link to review the publication )

J Cell Mol Med, 2016, 20(12):2289-2298

PubMed: 27420561 ( click the link to review the publication )

Horm Cancer, 2016, 7(3):196-210

PubMed: 26957440 ( click the link to review the publication )

Nat Microbiol, 2016, 1:16174

PubMed: 27694949 ( click the link to review the publication )

J Immunol, 2015, 195(11):5421-31

PubMed: 26519528 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

BMC Biol, 2014, 12:95

PubMed: 25406762 ( click the link to review the publication )

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767 ( click the link to review the publication )

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述

靶点

HDAC8 ^[1]
(Cell-free assay)

10 nM

体外研究

PCI-34051有效作用于HDAC8，K_i为10 nM。与其他I型HDACs包括HDAC1相比，PCI-34051更高选择性作用于HDAC8。比作用于HDAC1和HDAC6选择性高200倍，比作用于 HDAC2, HDAC3 和HDAC10选择性高1000倍。PCI-34051抑制卵巢瘤细胞系OVCAR-3，GI50为6 μM，细胞死亡率为15%。PCI-34051浓度低于25 μM 时，处理敏感细胞系，在24小时而非更早时间点，观察不到显著的微管蛋白，也观察不到组蛋白乙酰化。PCI-34051 作用于T细胞恶性肿瘤衍生的细胞系，诱导选择性的细胞毒性作用。PCI-34051 诱导caspase依赖性凋亡。使用5 μM PCI-34051处理后，在不同时间点测量caspase-3活性, 在12 到24 到48 小时观察到活性水平提高，凋亡的另一种标志, 与更高水平caspase 活性一致。PCI-34051不刺激 Bid 分裂, Bid 分裂是外在凋亡通路的特性影响。P116 和 J.RT3-T.5 对PCI-34051敏感，PLCγ1缺陷的J.gamma1系显著降低 PCI-34051诱导凋亡的程度。此外, 稳定的钙水平也强烈影响PCI-34051诱导的凋亡。PCI-34051诱导细胞色素 c从线粒体中释放。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
LAN1	NVXYT4NsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWDKcWFFPzJiaILz	M3LkdGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGxCVjFiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgUXRUKGG\|c3H5MEBIUTVyPUOuPe69VQ>?	M165VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUG2NVQ4Lz5{M{GxOlE1PzxxYU6=
Jurkat	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoCzO\|IhcHK\|	NYnhRpJpT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUnW{a3H0JINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KE2WUzDhd5NigSxiR1m1NF0yOc7:TR?=	NHjEZmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{GxOlE1Pyd-MkOxNVYyPDd:L3G+
NB-1	M4CwU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXG3NkBpenN?	M3zYfGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5DNTFiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgUXRUKGG\|c3H5MEBIUTVyPUG0{txO	MnT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzMU[xOFcoRjJ\|MUG2NVQ4RC:jPh?=
MT2	M3HmN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NV3JW4o5PzJiaILz	M{LLV2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1VOiClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGdKPTB;MUZOwG0>	M1;QW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUG2NVQ4Lz5{M{GxOlE1PzxxYU6=
MT4	NFzJTYNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXjDUHF1PzJiaILz	NUX3cmJDT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVVR2IHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhT0l3ME2yOe69VQ>?	NWHCPHlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxNVYyPDdpPkKzNVE3OTR5PD;hQi=>
Huh7	NGPGNo1CdnSrdnnyZYwh[XO\|YYm=		NHr4W5Y{KGSjeYO=	Mn7hRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGNXKGenbn;0fZBmKDGkIHnu[oVkfGWmIHnuJIh2dWGwIFj1bFch[2WubIOgZYZ1\XJiMzDkZZl{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2xMljPxE1?	NI\QOnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS5NFcxOCd-MkW0PVA4ODB:L3G+
HuH7	MmrkR5l1d3SxeHnjbZR6KGG\|c3H5		M13BdVMh\GG7cx?=	NF\kbWtEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJfUh5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDD2bYFjcWyrdImgZYZ1\XJiMzDkZZl{KGK7IFPlcIxVcXSncjC5OkBie3OjeTygR2M2OD1zMd88US=>	MkHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OUC3NFAoRjJ3NEmwO\|AxRC:jPh?=
Sf9	MWrGeY5kfGmxbjDhd5NigQ>?		Mn3JOUBucW6\|	M4XON2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSg[pVtdC2uZX7neIghcHWvYX6gR{11\XKvaX7hcEBHVEGJLVjpd{11[WepZXSgTGRCSzFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDpcpNm[3RiY3XscJMhfXOrbnegRo9kNUxvTInzLGFkMS2DTVOgZZMhe3Wkc4TyZZRmKHC{ZXnuZ5Vj[XSnZDDmc5IhPSCvaX7zJIZwdGyxd3XkJIJ6KHO3YoP0doF1\SCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkA{PSCvaX7zJIJ6KG[udX;y[ZNk\SxiSVO1NF0{NjkQvF2=	NHz2fHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOVc6Pid-Mki4N\|U4QTZ:L3G+
Sf9	MXPGeY5kfGmxbjDhd5NigQ>?		MkHlOUBucW6\|	NUe1fFMxUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtNWynbnf0bEBENXSncn3pcoFtKEircz30ZYdo\WRiSFTBR\|MhMDN7NTD0c{A1QDlicnXzbYR2\XNrL3j1cYFvKE6FT2KyJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDT[lkhcW6\|ZXP0JINmdGy\|IIXzbY5oKEKxYz3MMWx6eyiDYzmtRW1EKGG\|IIP1ZpN1emG2ZTDwdoV1emWjdHXkJIZweiB3IH3pcpMh\m:ubH;3[YQh[nlic4Xid5Rz[XSnIHHk[Il1cW:wIH3lZZN2emWmLDDJR\|UxRTdwMd88US=>	NXO4PXVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4N\|U4QTZpPkK4PFM2Pzl4PD;hQi=>
Sf9	MVfGeY5kfGmxbjDhd5NigQ>?		MW[1JI1qdnN?	NFGycVBKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwudGWwZ4ToJGMufGW{bXnuZYwhUGm\|LYTh[4dm\CCKRFHDNkBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4Y6KGmwc3XjeEBk\WyuczD1d4lv\yCEb3OtUE1NgXNqQXOpMWFOSyCjczDzeYJ{fHKjdHWgdJJmcW6ldXLheIVlKG[xcjC1JI1qdnNiZn;scI94\WRiYomgd5Vje3S{YYTlJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IEO1JI1qdnNiYomg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyPUOx{txO	NWX6SXM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4N\|U4QTZpPkK4PFM2Pzl4PD;hQi=>
SH-SY5Y	NH3pZXREgXSxdH;4bYNqfHliYYPzZZk>			NYr2UIw3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0hvU2m1XUBk\WyuczDlfJBz\XO\|aX7nJHRRPTNiYomgR4VtdFSrdHXyPVYhSVG3ZX;1d{BwdmVic3;seZRqd25iY3XscEBxem:uaX\ldoF1cW:wIHHzd4F6	NXL2NWtURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4N\|U4QTZpPkK4PFM2Pzl4PD;hQi=>
IMR5	MYrDfZRwfG:6aXPpeJkh[XO\|YYm=			MnXSR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTW1TPSClZXzsd{BmgHC{ZYPzbY5oKFSSNUOgZpkhS2WubGTpeIVzQTZiQWH1[Y92eyCxbnWgd49tfXSrb36gZ4VtdCCycn;sbYZmemG2aX;uJIF{e2G7	MlL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6M{W3PVYoRjJ6OEO1O\|k3RC:jPh?=
SK-N-AS	NX7ES2JXS3m2b4TvfIlkcXS7IHHzd4F6			NFPvOIJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2QLVHTJINmdGy\|IHX4dJJme3OrbnegWHA2OyCvdYTheIlwdiCkeTDD[YxtXGm2ZYK5OkBCWXWnb4XzJI9v\SC\|b3z1eIlwdiClZXzsJJBzd2yrZnXyZZRqd25iYYPzZZk>	NEW4WZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOVc6Pid-Mki4N\|U4QTZ:L3G+
Kelly	MoO1R5l1d3SxeHnjbZR6KGG\|c3H5			M{\hfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtmdGy7IHPlcIx{KGW6cILld5NqdmdiVGC1N{BufXSjdHnvckBjgSCFZXzsWIl1\XJ7NjDBVZVmd3W\|IH;u[UB{d2y3dHnvckBk\WyuIIDyc4xq\mW{YYTpc44h[XO\|YYm=	NHHkfY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOVc6Pid-Mki4N\|U4QTZ:L3G+
BE(2)-C	NEHIZYFEgXSxdH;4bYNqfHliYYPzZZk>		Moj0O\|IhcHK\|	MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCSUgzMS2FIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDifUBu\WG\|dYLpcochdWW2YXLvcIlkKGGldHn2bZR6KGGodHXyJFczKGi{czDifUBYW1RvODDhd5NigSxiSVO1NF0yQS57zszN	NELsOos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG5NFA6Oid-MkmxPVAxQTJ:L3G+
Sf9	M2j0dGZ2dmO2aX;uJIF{e2G7		NHzkTWg6OCCvaX7z	NYnNSVNnUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtKGynbnf0bEBENXSncn3pcoFtKE[OQVeteIFo\2WmIFjERWMyKGW6cILld5Nm\CCrbjDmZYxtKGG{bYn3c5JuKFOoOTDj[YxteyC3c3nu[{BndHWxcn;n[Y5q[yCcTVHMJIF{KHO3YoP0doF1\SCjZoTldkA6OCCvaX7zJIJ6KG[udX;ybY1mfHKrYzDhcoFtgXOrczygTWM2OD1{OD6z{txO	M{SwPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUmwNFkzLz5{OUG5NFA6OjxxYU6=
Sf9	Ml\LSpVv[3Srb36gZZN{[Xl?		NGDjV5g6OCCvaX7z	M{K0RWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigTGRCSzZiZYjwdoV{e2WmIHnuJIZidGxiYYLtfZdwem1iU3[5JINmdGy\|IIXzbY5oKG[udX;yc4dmdmmlIGrNRWwh[XNic4Xid5Rz[XSnIHHmeIVzKDlyIH3pcpMh[nliZnz1c5JqdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPUS4MlLPxE1?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF7MEC5Nkc,OjlzOUCwPVI9N2F-
BE(2)-C	MUjGeY5kfGmxbjDhd5NigQ>?	NF7PfnE3KHWP	NH3abWk4OiCqcoO=	NHXafItKdmirYnn0bY9vKG:oIFjERWM5KGmwIHj1cYFvKEKHKEKpMWMh[2WubIOgZZN{\XO\|ZXSgZZMhfXC{ZXf1cIF1cW:wIH;mJJAzOS:FRFvONUBo\W6nIHX4dJJme3Orb36gZZQhPiC3TTDh[pRmeiB5MjDodpMh[nliUmStVGNTKGGwYXz5d4l{KHKnbHH0bZZmKHSxIHPvcpRzd2x?	NF;EZXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG5NFA6Oid-MkmxPVAxQTJ:L3G+
BE(2)-C	NEXMVFFHfW6ldHnvckBie3OjeR?=	M{LlVVYhfU1?	MmTDO\|IhcHK\|	MX;Jcohq[mm2aX;uJI9nKEiGQVO4JIlvKGi3bXHuJGJGMDJrLVOgZ4VtdHNiYYPz[ZN{\WRiYYOgeZBz\We3bHH0bY9vKG:oIGTyb2EwVlSUS{Gg[4Vv\SCneIDy[ZN{cW:wIHH0JFYhfU1iYX\0[ZIhPzJiaILzJIJ6KFKWLWDDVkBidmGueYPpd{Bz\WyjdHn2[UB1dyClb370do9t	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF7MEC5Nkc,OjlzOUCwPVI9N2F-
BE(2)-C	MnfkSpVv[3Srb36gZZN{[Xl?	MkjWOkB2VQ>?	NVnKd4NMPzJiaILz	MorvTY5pcWKrdHnvckBw\iCKRFHDPEBqdiCqdX3hckBDTSh{KT3DJINmdGy\|IHHzd4V{e2WmIHHzJJVxemWpdXzheIlwdiCxZjDUTEBo\W6nIHX4dJJme3Orb36gZZQhPiC3TTDh[pRmeiB5MjDodpMh[nliUmStVGNTKGGwYXz5d4l{KHKnbHH0bZZmKHSxIHPvcpRzd2x?	MnPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzOUCwPVIoRjJ7MUmwNFkzRC:jPh?=
BE(2)-C	MkjvSpVv[3Srb36gZZN{[Xl?	MX62JJVO	NEPDbG43KGSjeYO=	M2rwVGlv\HWldHnvckBw\iCxdYTndo94fGhib3[gcoV2em:oaXzhcYVvfCCyb4PpeIl3\SCwZYX0dol1\S2uaXvlJJN1enWldIXy[ZMhcW5iaIXtZY4hSkVqMjmtR{Bk\WyuczDheEA3KHWPIHHmeIVzKDZiZHH5d{BjgSCGQWDJMZN1[WmwaX7nJIJie2WmIH3pZ5Jwe2OxcHnjJIFv[Wy7c3nz	M{XPbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUmwNFkzLz5{OUG5NFA6OjxxYU6=
A673	MkLmdWhVWyCjc4PhfS=>			MX\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	M2\scFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	MXvxTHRUKGG\|c3H5			MVLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NU\1So05RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	NYfmO5oxeUiWUzDhd5NigQ>?			NXvzS\|Y5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	Mn;nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	M1zicpFJXFNiYYPzZZk>			MU\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	M3riZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	MVfxTHRUKGG\|c3H5			NWnvT3RIeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	NYTXSGk5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5	MknKdWhVWyCjc4PhfS=>			NXnmfpVEeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	MmfwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Jurkat	M3O4dmFvfGmycn;sbYZmemG2aY\lJIF{e2G7			MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEq3cnvheEBk\WyuczDifUBidGGvYYKgZox2\SCjc4PhfUwhT0l3ME2yMlTPxE1?	NXPMRpNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1NFU6OzVpPkK5OVA2QTN3PD;hQi=>
HUT78	NGO4fWpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			NIHvRZBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjVWFc5KGOnbHzzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCJSUWwQVIvPM7:TR?=	NXi0WHlbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1NFU6OzVpPkK5OVA2QTN3PD;hQi=>
HSB2	M3PieWFvfGmycn;sbYZmemG2aY\lJIF{e2G7			NVXYXZRySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIV2IzKGOnbHzzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCJSUWwQVIvPM7:TR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVyNUmzOUc,Ojl3MEW5N\|U9N2F-
MOLT4	MXXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			M3HSXGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MWFQh[2WubIOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEeLNUC9Nk41\|ryP	NE\NWpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWwOVk{PSd-Mkm1NFU6OzV:L3G+
Jurkat	NIPYSIxCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MkHhOFghcHK\|	M{\UfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSoXyb4F1KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;ND61{txO	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV\|M{i3N{c,Ojl3M{O4O\|M9N2F-
MOLT4	MlTLRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MXy0PEBpenN?	NFnOVYtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUHQ1KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;OT60{txO	NHOxdYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzN\|g4Oyd-Mkm1N\|M5PzN:L3G+
HEL	NIHNN\|ZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NHG4d5I1QCCqcoO=	NVHYSnNZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDISWwh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zMD64{txO	NWT4dXZ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|M5PzNpPkK5OVM{QDd\|PD;hQi=>
SK-N-BE(2)	M4rWTWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MoS1OFghcHK\|	NGnleZBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMW4uSkVqMjmgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yPi57zszN	MoSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{O4O\|MoRjJ7NUOzPFc{RC:jPh?=
PC3	NVTUVIRvSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NU\1OmYzPDhiaILz	NH:xUmpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTF7LkNOwG0>	NYLCN5RYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|M5PzNpPkK5OVM{QDd\|PD;hQi=>
K562	MoDQRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NEjSXHM4OiCqcoO=	MkTaRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNNU[yJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFfJOVA:Oi5yMd88US=>	M3HqXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEC0Olk4Lz5\|MECwOFY6PzxxYU6=
K562R	MoHrRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M1niRlczKGi{cx?=	MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkLSJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFfJOVA:Oi5{zszN	NWj0R3pORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFQ3QTdpPkOwNFA1Pjl5PD;hQi=>
HCT116	NG\YNGZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MWe3NkBpenN?	NYPOfIxmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhT0l3ME2yMlY1\|ryP	NVH1UGRLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFQ3QTdpPkOwNFA1Pjl5PD;hQi=>
PC3	NYXDO3VGSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVnlfVJSPzJiaILz	Ml;HRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{OgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiR1m1NF0zNjZ4zszN	NWH6NZdoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFQ3QTdpPkOwNFA1Pjl5PD;hQi=>
MCF7	M2HLdGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M4TCVlczKGi{cx?=	Ml2wRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFfJOVA:Oi57N988US=>	NEfmbJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECwOFY6Pyd-M{CwNFQ3QTd:L3G+
BL21 (DE3)	MYLGeY5kfGmxbjDhd5NigQ>?			M{[wWGJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6gTIl{NXSqaX;y[YRwgGmwLYTh[4dm\CCKRFHDPEBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJEhFTTNrIHPlcIx{KGK7IFnUR{Bu\XSqb3SsJGtlRTBwMEe1Ne69VQ>?	MkPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NEexOFgoRjNyM{S3NVQ5RC:jPh?=
BL21 (DE3)	NXPEXlNuTnWwY4Tpc44h[XO\|YYm=			M1X5[WlvcGmkaYTpc44hd2ZiaIXtZY4hUGm\|LYTobY9z\WSxeHnuMZRi\2enZDDISGFEQCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKCiGRUOpJINmdGy\|IIXzbY5oKE[udX;yJIRmKEy7czCoVkkuUESDQ{igZZMhe3Wkc4TyZZRmKGK7IH\seY9zd22ndILpZ{Bu\XSqb3SsJGlEPTB;MD6wO\|c4\|ryP	NFHLWlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO0O\|E1QCd-M{CzOFcyPDh:L3G+
BL21 (DE3)	NWjUSIx4TnWwY4Tpc44h[XO\|YYm=			M1nGc2JqdmSrbnegZYZncW6rdImgeI8hW2OqaYP0c5NwdWFibXHud49vcSCKaYOteIFo\2WmIFjERWM5KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEhMESHMzmgZ4VtdHNiYomgTXREKG2ndHjv[EwhU2R;MD6zOlfPxE1?	NHWxNpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO0O\|E1QCd-M{CzOFcyPDh:L3G+
BL21 (DE3)	NEnHVXJHfW6ldHnvckBie3OjeR?=			NIWycGRKdmirYnn0bY9vKG:oIGPjbIl{fG:\|b33hJI1idnOxbnmgTIl{NXSjZ3fl[EBJTEGFODDlfJBz\XO\|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBDVDJzIDjESVMqKGOnbHzzJJV{cW6pIF\seY9zKGSnIFz5d{ApWilvSFTBR\|gh[XNic4Xid5Rz[XSnIHL5JIZtfW:{b33leJJq[yCvZYToc4QtKEmFNUC9NE41OzV6zszN	M4jWXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{S3NVQ5Lz5\|MEO0O\|E1QDxxYU6=
BL21 (DE3)	NFTHR3NHfW6ldHnvckBie3OjeR?=			MYnJcohq[mm2aX;uJI9nKGi3bXHuJGhqey22aHnvdoVld3irbj30ZYdo\WRiSFTBR\|ghdUx4L1yxO\|lKKG23dHHueEBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJEhFTTNrIHPlcIx{KHW\|aX7nJGZtfW:{IHTlJGx6eyBqUjmtTGRCSzhiYYOgd5Vje3S{YYTlJIJ6KG[udX;yc41mfHKrYzDt[ZRpd2RuIFnDOVA:Oc7:TR?=	M3XyeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{S3NVQ5Lz5\|MEO0O\|E1QDxxYU6=
BL21 (DE3)	M3vWS2Z2dmO2aX;uJIF{e2G7			M1O4[mlvcGmkaYTpc44hd2ZiaIXtZY4hUGm\|LYTobY9z\WSxeHnuMZRi\2enZDDISGFEQCCvTE[gcZV1[W62IHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFiKFTFN{kh[2WubIOgeZNqdmdiRnz1c5Ih\GViTInzJEhTMS2KRFHDPEBieyC\|dXLzeJJifGViYomg[ox2d3KxbXX0dolkKG2ndHjv[EwhUUN3ME2xMlY{\|ryP	NHLB[Ho9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO0O\|E1QCd-M{CzOFcyPDh:L3G+
BL21 (DE3)	Mli3SpVv[3Srb36gZZN{[Xl?			M4f4fGlvcGmkaYTpc44hd2ZiaIXtZY4hUGm\|LYTobY9z\WSxeHnuMZRi\2enZDDISGFEQCCvTEGvcWw3KG23dHHueEBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJEhFTTNrIHPlcIx{KHW\|aX7nJGZtfW:{IHTlJGx6eyBqUjmtTGRCSzhiYYOgd5Vje3S{YYTlJIJ6KG[udX;yc41mfHKrYzDt[ZRpd2RuIFnDOVA:Oi55zszN	NXHFVW9lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOFcyPDhpPkOwN\|Q4OTR6PD;hQi=>
BL21 (DE3)	NGe2R2xHfW6ldHnvckBie3OjeR?=			MkDQTY5pcWKrdHnvckBw\iCqdX3hckBJcXNvdHjpc5Jm\G:6aX6teIFo\2WmIFjERWM5KG2OMT;tUFYwVDF5OVmgcZV1[W62IHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFiKFTFN{kh[2WubIOgeZNqdmdiRnz1c5Ih\GViTInzJEhTMS2KRFHDPEBieyC\|dXLzeJJifGViYomg[ox2d3KxbXX0dolkKG2ndHjv[EwhUUN3ME21{txO	NIfXfmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO0O\|E1QCd-M{CzOFcyPDh:L3G+
Sf9	M4PE[mZ2dmO2aX;uJIF{e2G7			MnnaTY5pcWKrdHnvckBw\iCFLYTldo1qdmGuIF\MRWcwUGm\|LYTh[4dm\CCodXzsJIxmdme2aDDoeY1idiCKRFHDNUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4Y6KGmwc3XjeEBk\WyuczD1d4lv\yCcKFHjLWx6ey2DTVOgZZMhe3Wkc4TyZZRmKGK7IH\seY9zd22ndILpZ{Bu\XSqb3SsJGlEPTB;MkiuN:69VQ>?	NFLL[Vg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO0O\|E1QCd-M{CzOFcyPDh:L3G+
Sf9	NEmwTW9HfW6ldHnvckBie3OjeR?=			NHrvcYlKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBnfWyuIHzlcod1cCCqdX3hckBJTEGFNjDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[5JIlve2WldDDj[YxteyC3c3nu[{BbMEGlKVz5d{1CVUNiYYOgd5Vje3S{YYTlJIJ6KG[udX;yc41mfHKrYzDt[ZRpd2RuIFnDOVA:PDhwMt88US=>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN2N{G0PEc,OzB\|NEexOFg9N2F-
Sf9	NHHCXHNHfW6ldHnvckBie3OjeR?=		NEX2OpU1OCCvaX7z	MVXJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIFOteIVzdWmwYXygTIl{NXSjZ3fl[EBJTEGFODDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiaX7z[YN1KGOnbHzzJI1m[XO3cnXkJIFnfGW{IESwJI1qdnNiYomgTGRCSy2JbH:xM\|IhdHWvaX7ld4NmdnRiYYPzZZktKEmFNUC9NE4xOzF4Mt88US=>	M1rWOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOU[0NlkxLz5\|MEm2OFI6ODxxYU6=
SK-N-BE(2)C	NI\HdFdCdnSrY3zvco9o\W6rYzDhd5NigQ>?		MUC5OkBpenN?	NWCyPFJoSW62aXPsc45w\2WwaXOgZYN1cX[rdImgbY4hcHWvYX6gV2suVi2ERTiyLWMh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwheHKxbHnm[ZJifGmxbjDpcoN2[mG2ZXSg[o9zKDl4IHjyd{BjgSClconzeIFtKH[rb3zleEB{fGGrbnnu[{Bj[XOnZDDhd5NigSxiR1m1NF0yPc7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTZ\|MEC1OEc,OzF4M{CwOVQ9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Immunofluorescence	SMC3 / Ac-SMC3 ; PubMed: 27072133 J Biol Chem A and B, representative immunofluorescence analysis of total- and ac-SMC3 in G1-S synchronized MCF7 cells treated with the indicated concentrations of PCI-34051 for 6 and 12 h, respectively. MCF7 cells grown in complete medium were synchronized to G1-S phase by double thymidine block and released in the presence of different concentrations of PCI-34051 for 6 or 12 h. Cells were stained for DNA (Hoechst-H33342, blue) and with antibodies detecting total-SMC3 (green) and ac-SMC3 (red). Cells were analyzed by Nikon C2 confocal microscope; images were taken at 20× magnification (z-series) using the NIS elements software, z-stacked, and processed using FIJI.	27072133

激酶实验：^[1]	- 合并组蛋白去乙酰化酶活性: 使用96孔实验板上，反应体积为100 μL，在荧光酶标仪上测量PCI-34051特性。HDAC 蛋白在反应buffer (50 mM HEPES, 100 mM KCl, 0.001% Tween-20, 5% DMSO, pH7.4,伴有牛血清蛋白，浓度为0-0.05%)中与不同浓度PCI-34051混合，再温育15分钟，测定每种酶。加入胰蛋白酶，终浓度为50 nM,加入乙酰基-gly-Ala-(N-乙酰基-Lys)-氨基-4-甲基香豆素，终浓度为25-100 μM，开始反应。停滞30分钟后, 使用激发波长为335 nm，检测波长为460 nm，在30分钟时间范围测量荧光值。测量的荧光值的增量用了衡量反应速率。
细胞实验：^[1]	- 合并 Cell lines: A549 细胞系, Ovcar-3 细胞系 Concentrations: 5 μM Incubation Time: 24 小时 Method: 肿瘤细胞系和人脐静脉内皮细胞培养至少两次倍增时间，PCI-34051处理末期，通过Alamar Blue荧光细胞增殖检测实验监测生长。PCI-34051重复三份加入96孔板中。使用四参数方程，通过非线性回归估量抑制 50% 细胞生长所需浓度(GI50)和95%置信区间。 (Only for Reference)

参考文献

[1] Balasubramanian S, et al. Leukemia. 2008, 22(5), 1026-1034.

溶解度 (25°C)

体外	DMSO	59 mg/mL (199.1 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+40%PEG300+5% tween80+50% H2O	5 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download PCI-34051 SDF

分子量	296.32
化学式	C₁₇H₁₆N₂O₃
CAS号	950762-95-5
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

泛HDAC抑制剂

Panobinostat (LBH589) : Pan-HDAC inhibitor, IC50=5 nM.
活性最高的HDAC抑制剂

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA批准的HDAC抑制剂

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
最新的HDAC抑制剂

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

研究领域

产品类型

定制您的化合物库

PCI-34051

客户使用Selleck生产的PCI-34051发表文献39篇：

产品安全说明书

HDAC抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download PCI-34051 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品